Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial

Acromegaly

(2019) Annamaria Colao et al.   Nature Reviews Disease Primers

ANNIVERSARY REVIEW: Octreotide, 40 years later

(2019) Steven W J Lamberts et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update

(2019) Andrea Giustina et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant

(2018) Christian J Strasburger et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A Consensus Statement on acromegaly therapeutic outcomes

(2018) Shlomo Melmed et al.   Nature Reviews Endocrinology

Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY

(2018) Michael Buchfelder et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Diagnosis and Treatment of Pituitary Adenomas

(2017) Mark E. Molitch   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)

(2017) Ammar Muhammad et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study

(2017) Vivien Bonert et al.   Pituitary

Somatostatin receptor ligands in the treatment of acromegaly

(2017) Monica R. Gadelha et al.   Pituitary

Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY

(2016) Aart Jan van der Lely et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Pituitary Medicine From Discovery to Patient-Focused Outcomes

(2016) Shlomo Melmed   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly

(2015) Cristina Capatina et al.   JOURNAL OF ENDOCRINOLOGY

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

(2015) Annamaria Colao et al.   Pituitary

Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly

(2014) S. J. C. M. M. Neggers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis

(2014) John D. Carmichael et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly: An Endocrine Society Clinical Practice Guideline

(2014) Laurence Katznelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly

(2012) Nicholas F. Marko et al.   JOURNAL OF NEUROSURGERY

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly

(2012) Andrea Giustina et al.   PLoS One

Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients

(2011) Michael Madsen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

(2010) Aart-Jan van der Lely et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients

(2009) SJCMM Neggers et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study

(2009) Annamaria Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Growth hormone receptor modulators

(2008) Vita Birzniece et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS